Liposomal Nanoformulation as a Carrier for Curcumin and pEGCG—Study on Stability and Anticancer Potential
Abstract
:1. Introduction
2. Materials and Methods
2.1. Chemical Compounds and Reagents
2.2. Liposome Preparation
2.3. Liposome Size and Zeta Potential Measurement
2.4. HPLC Analysis
2.5. Biological Activity Assessment
2.6. Statistical Analysis
3. Results and Discussion
3.1. Liposome Size
3.2. Liposomal Formulation Stability Study
3.2.1. Particle Size and Particle Concentration
3.2.2. Stability Study at Room (20 °C) and Refrigerator (4–8 °C) Temperatures
3.3. Biological Activity
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Hass, R.; Jennek, S.; Yang, Y.; Friedrich, K. C-Met Expression and Activity in Urogenital Cancers—Novel Aspects of Signal Transduction and Medical Implications. Cell Commun. Signal. 2017, 15, 10. [Google Scholar] [CrossRef] [Green Version]
- Saginala, K.; Barsouk, A.; Aluru, J.S.; Rawla, P.; Padala, S.A.; Barsouk, A. Epidemiology of Bladder Cancer. Med. Sci. 2020, 8, 15. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zaghloul, M.S.; Zaghloul, T.M.; Bishr, M.K.; Baumann, B.C. Urinary Schistosomiasis and the Associated Bladder Cancer: Update. J. Egypt. Natl. Cancer Inst. 2020, 32, 44. [Google Scholar] [CrossRef] [PubMed]
- Lenis, A.T.; Lec, P.M.; Chamie, K.; Mshs, M.D. Bladder Cancer: A Review. JAMA 2020, 324, 1980–1991. [Google Scholar] [CrossRef] [PubMed]
- Magers, M.J.; Lopez-Beltran, A.; Montironi, R.; Williamson, S.R.; Kaimakliotis, H.Z.; Cheng, L. Staging of Bladder Cancer. Histopathology 2019, 74, 112–134. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Piwowarczyk, L.; Stawny, M.; Mlynarczyk, D.T.; Muszalska-Kolos, I.; Goslinski, T.; Jelińska, A. Role of Curcumin and (−)-Epigallocatechin-3-O-Gallate in Bladder Cancer Treatment: A Review. Cancers 2020, 12, 1801. [Google Scholar] [CrossRef]
- De George, K.C.; Holt, H.R.; Hodges, S.C. Bladder Cancer: Diagnosis and Treatment. Am. Fam. Physician 2017, 96, 507–514. [Google Scholar]
- Babjuk, M.; Böhle, A.; Burger, M.; Capoun, O.; Cohen, D.; Compérat, E.M.; Hernández, V.; Kaasinen, E.; Palou, J.; Rouprêt, M.; et al. EAU Guidelines on Non-Muscle-Invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur. Urol. 2017, 71, 447–461. [Google Scholar] [CrossRef]
- Teo, M.Y.; Rathkopf, D.E.; Kantoff, P. Treatment of Advanced Prostate Cancer. Annu. Rev. Med. 2019, 70, 479–499. [Google Scholar] [CrossRef]
- Cory, H.; Passarelli, S.; Szeto, J.; Tamez, M.; Mattei, J. The Role of Polyphenols in Human Health and Food Systems: A Mini-Review. Front. Nutr. 2018, 5, 87. [Google Scholar] [CrossRef] [Green Version]
- Min, K.; Kwon, T.K. Anticancer Effects and Molecular Mechanisms of Epigallocatechin-3-Gallate. Integr. Med. Res. 2014, 3, 16–24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Krupkova, O.; Ferguson, S.J.; Wuertz-Kozak, K. Stability of (−)-Epigallocatechin Gallate and Its Activity in Liquid Formulations and Delivery Systems. J. Nutr. Biochem. 2016, 37, 1–12. [Google Scholar] [CrossRef]
- Pari, L.; Tewas, D.; Eckel, J. Role of Curcumin in Health and Disease. Arch. Physiol. Biochem. 2008, 114, 127–149. [Google Scholar] [CrossRef]
- Rahmani, A.H.; Alsahli, M.A.; Aly, S.M.; Khan, M.A.; Aldebasi, Y.H. Role of Curcumin in Disease Prevention and Treatment. Adv. Biomed. Res. 2018, 7, 38. [Google Scholar] [CrossRef]
- Sharifi-Rad, J.; Rayess, Y.E.; Rizk, A.A.; Sadaka, C.; Zgheib, R.; Zam, W.; Sestito, S.; Rapposelli, S.; Neffe-Skocińska, K.; Zielińska, D.; et al. Turmeric and Its Major Compound Curcumin on Health: Bioactive Effects and Safety Profiles for Food, Pharmaceutical, Biotechnological and Medicinal Applications. Front. Pharmacol. 2020, 11, 01021. [Google Scholar] [CrossRef]
- A Novel Curcumin Derivative Which Inhibits P-Glycoprotein, Arrests Cell Cycle and Induces Apoptosis in Multidrug Resistance Cells—ScienceDirect. Available online: https://www.sciencedirect.com/science/article/abs/pii/S0968089616311890 (accessed on 30 December 2021).
- Maleki Dizaj, S.; Alipour, M.; Dalir Abdolahinia, E.; Ahmadian, E.; Eftekhari, A.; Forouhandeh, H.; Rahbar Saadat, Y.; Sharifi, S.; Zununi Vahed, S. Curcumin Nanoformulations: Beneficial Nanomedicine against Cancer. Phytother. Res. 2022, 36, 1156–1181. [Google Scholar] [CrossRef] [PubMed]
- Karthikeyan, A.; Senthil, N.; Min, T. Nanocurcumin: A Promising Candidate for Therapeutic Applications. Front. Pharmacol. 2020, 11, 487. [Google Scholar] [CrossRef] [PubMed]
- Liu, G.; Hou, S.; Tong, P.; Li, J. Liposomes: Preparation, Characteristics, and Application Strategies in Analytical Chemistry. Crit. Rev. Anal. Chem. 2022, 52, 392–412. [Google Scholar] [CrossRef]
- Patil, Y.P.; Jadhav, S. Novel Methods for Liposome Preparation. Chem. Phys. Lipids 2014, 177, 8–18. [Google Scholar] [CrossRef]
- Li, M.; Du, C.; Guo, N.; Teng, Y.; Meng, X.; Sun, H.; Li, S.; Yu, P.; Galons, H. Composition Design and Medical Application of Liposomes. Eur. J. Med. Chem. 2019, 164, 640–653. [Google Scholar] [CrossRef]
- Liu, P.; Chen, G.; Zhang, J. A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives. Molecules 2022, 27, 1372. [Google Scholar] [CrossRef] [PubMed]
- Kohri, T.; Nanjo, F.; Suzuki, M.; Seto, R.; Matsumoto, N.; Yamakawa, M.; Hojo, H.; Hara, Y.; Desai, D.; Amin, S.; et al. Synthesis of (−)-[4-3H]Epigallocatechin Gallate and Its Metabolic Fate in Rats after Intravenous Administration. J. Agric. Food Chem. 2001, 49, 1042–1048. [Google Scholar] [CrossRef]
- Piskorz, J.; Mlynarczyk, D.T.; Szczolko, W.; Konopka, K.; Düzgüneş, N.; Mielcarek, J. Liposomal Formulations of Magnesium Sulfanyl Tribenzoporphyrazines for the Photodynamic Therapy of Cancer. J. Inorg. Biochem. 2018, 184, 34–41. [Google Scholar] [CrossRef] [PubMed]
- Hudiyanti, D.; Khafiz, M.F.A.; Anam, K.; Siahaan, P.; Suyati, L. Assessing Encapsulation of Curcumin in Cocoliposome: In Vitro Study. Open Chem. 2021, 19, 358–366. [Google Scholar] [CrossRef]
- Zhang, H. Thin-Film Hydration Followed by Extrusion Method for Liposome Preparation. Methods Mol. Biol. 2017, 1522, 17–22. [Google Scholar] [CrossRef] [PubMed]
- Shimoda, A.; Tahara, Y.; Sawada, S.; Sasaki, Y.; Akiyoshi, K. Glycan Profiling Analysis Using Evanescent-Field Fluorescence-Assisted Lectin Array: Importance of Sugar Recognition for Cellular Uptake of Exosomes from Mesenchymal Stem Cells. Biochem. Biophys. Res. Commun. 2017, 491, 701–707. [Google Scholar] [CrossRef] [PubMed]
- Filipe, V.; Hawe, A.; Jiskoot, W. Critical Evaluation of Nanoparticle Tracking Analysis (NTA) by NanoSight for the Measurement of Nanoparticles and Protein Aggregates. Pharm. Res. 2010, 27, 796–810. [Google Scholar] [CrossRef] [Green Version]
- Sato, Y.T.; Umezaki, K.; Sawada, S.; Mukai, S.; Sasaki, Y.; Harada, N.; Shiku, H.; Akiyoshi, K. Engineering Hybrid Exosomes by Membrane Fusion with Liposomes. Sci. Rep. 2016, 6, 21933. [Google Scholar] [CrossRef] [Green Version]
- van Meerloo, J.; Kaspers, G.J.L.; Cloos, J. Cell Sensitivity Assays: The MTT Assay. In Cancer Cell Culture: Methods and Protocols; Cree, I.A., Ed.; Methods in Molecular Biology; Humana Press: Totowa, NJ, USA, 2011; pp. 237–245. ISBN 978-1-61779-080-5. [Google Scholar]
- Mosmann, T. Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays. J. Immunol. Methods 1983, 65, 55–63. [Google Scholar] [CrossRef]
- Kucinska, M.; Piotrowska-Kempisty, H.; Lisiak, N.; Kaczmarek, M.; Dams-Kozlowska, H.; Granig, W.H.; Höferl, M.; Jäger, W.; Zehl, M.; Murias, M.; et al. Selective Anticancer Activity of the Novel Thiobenzanilide 63T against Human Lung Adenocarcinoma Cells. Toxicol. Vitr. 2016, 37, 148–161. [Google Scholar] [CrossRef]
- Yan, X.; Zhang, X.; McClements, D.J.; Zou, L.; Liu, X.; Liu, F. Co-Encapsulation of Epigallocatechin Gallate (EGCG) and Curcumin by Two Proteins-Based Nanoparticles: Role of EGCG. J. Agric. Food Chem. 2019, 67, 13228–13236. [Google Scholar] [CrossRef] [PubMed]
- Chung, S.S.; Vadgama, J.V. Curcumin and Epigallocatechin Gallate Inhibit the Cancer Stem Cell Phenotype via Down-Regulation of STAT3–NFκB Signaling. Anticancer Res. 2015, 35, 39–46. [Google Scholar] [PubMed]
- Jin, G.; Yang, Y.; Liu, K.; Zhao, J.; Chen, X.; Liu, H.; Bai, R.; Li, X.; Jiang, Y.; Zhang, X.; et al. Combination Curcumin and (−)-Epigallocatechin-3-Gallate Inhibits Colorectal Carcinoma Microenvironment-Induced Angiogenesis by JAK/STAT3/IL-8 Pathway. Oncogenesis 2017, 6, e384. [Google Scholar] [CrossRef] [PubMed]
- Eom, D.-W.; Lee, J.H.; Kim, Y.-J.; Hwang, G.S.; Kim, S.-N.; Kwak, J.H.; Cheon, G.J.; Kim, K.H.; Jang, H.-J.; Ham, J.; et al. Synergistic Effect of Curcumin on Epigallocatechin Gallate-Induced Anticancer Action in PC3 Prostate Cancer Cells. BMB Rep. 2015, 48, 461–466. [Google Scholar] [CrossRef] [Green Version]
- Inglut, C.T.; Sorrin, A.J.; Kuruppu, T.; Vig, S.; Cicalo, J.; Ahmad, H.; Huang, H.-C. Immunological and Toxicological Considerations for the Design of Liposomes. Nanomaterials 2020, 10, 190. [Google Scholar] [CrossRef] [Green Version]
- Arab-Tehrany, E.; Elkhoury, K.; Francius, G.; Jierry, L.; Mano, J.F.; Kahn, C.; Linder, M. Curcumin Loaded Nanoliposomes Localization by Nanoscale Characterization. Int. J. Mol. Sci. 2020, 21, 7276. [Google Scholar] [CrossRef]
- Wu, Y.; Mou, B.; Song, S.; Tan, C.-P.; Lai, O.-M.; Shen, C.; Cheong, L.-Z. Curcumin-Loaded Liposomes Prepared from Bovine Milk and Krill Phospholipids: Effects of Chemical Composition on Storage Stability, in-Vitro Digestibility and Anti-Hyperglycemic Properties. Food Res. Int. 2020, 136, 109301. [Google Scholar] [CrossRef]
- Farokhzad, O.C.; Langer, R. Impact of Nanotechnology on Drug Delivery. ACS Nano 2009, 3, 16–20. [Google Scholar] [CrossRef]
- Lombardo, D.; Calandra, P.; Barreca, D.; Magazù, S.; Kiselev, M.A. Soft Interaction in Liposome Nanocarriers for Therapeutic Drug Delivery. Nanomaterials 2016, 6, 125. [Google Scholar] [CrossRef]
- de Morais Ribeiro, L.N.; Couto, V.M.; Fraceto, L.F.; de Paula, E. Use of Nanoparticle Concentration as a Tool to Understand the Structural Properties of Colloids. Sci. Rep. 2018, 8, 982. [Google Scholar] [CrossRef] [Green Version]
- Clayton, K.N.; Salameh, J.W.; Wereley, S.T.; Kinzer-Ursem, T.L. Physical Characterization of Nanoparticle Size and Surface Modification Using Particle Scattering Diffusometry. Biomicrofluidics 2016, 10, 054107. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Smith, M.C.; Crist, R.M.; Clogston, J.D.; McNeil, S.E. Zeta Potential: A Case Study of Cationic, Anionic, and Neutral Liposomes. Anal. Bioanal. Chem. 2017, 409, 5779–5787. [Google Scholar] [CrossRef]
- Varga, Z.; Fehér, B.; Kitka, D.; Wacha, A.; Bóta, A.; Berényi, S.; Pipich, V.; Fraikin, J.-L. Size Measurement of Extracellular Vesicles and Synthetic Liposomes: The Impact of the Hydration Shell and the Protein Corona. Colloids Surf. B Biointerfaces 2020, 192, 111053. [Google Scholar] [CrossRef] [PubMed]
- Tai, K.; Rappolt, M.; Mao, L.; Gao, Y.; Yuan, F. Stability and Release Performance of Curcumin-Loaded Liposomes with Varying Content of Hydrogenated Phospholipids. Food Chem. 2020, 326, 126973. [Google Scholar] [CrossRef] [PubMed]
- Danaei, M.; Dehghankhold, M.; Ataei, S.; Hasanzadeh Davarani, F.; Javanmard, R.; Dokhani, A.; Khorasani, S.; Mozafari, M.R. Impact of Particle Size and Polydispersity Index on the Clinical Applications of Lipidic Nanocarrier Systems. Pharmaceutics 2018, 10, 57. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Badran, M.; Shalaby, K.; Al-Omrani, A. Influence of the Flexible Liposomes on the Skin Deposition of a Hydrophilic Model Drug, Carboxyfluorescein: Dependency on Their Composition. Sci. World J. 2012, 2012, e134876. [Google Scholar] [CrossRef] [Green Version]
- Huang, M.; Liang, C.; Tan, C.; Huang, S.; Ying, R.; Wang, Y.; Wang, Z.; Zhang, Y. Liposome Co-Encapsulation as a Strategy for the Delivery of Curcumin and Resveratrol. Food Funct. 2019, 10, 6447–6458. [Google Scholar] [CrossRef]
- Lam, W.H.; Kazi, A.; Kuhn, D.J.; Chow, L.M.C.; Chan, A.S.C.; Ping Dou, Q.; Chan, T.H. A Potential Prodrug for a Green Tea Polyphenol Proteasome Inhibitor: Evaluation of the Peracetate Ester of (−)-Epigallocatechin Gallate [(−)-EGCG]. Bioorganic Med. Chem. 2004, 12, 5587–5593. [Google Scholar] [CrossRef]
- Lodi, A.; Saha, A.; Lu, X.; Wang, B.; Sentandreu, E.; Collins, M.; Kolonin, M.G.; DiGiovanni, J.; Tiziani, S. Combinatorial Treatment with Natural Compounds in Prostate Cancer Inhibits Prostate Tumor Growth and Leads to Key Modulations of Cancer Cell Metabolism. NPJ Precis. Oncol. 2017, 1, 18. [Google Scholar] [CrossRef]
- Akhtar, M.F.; Saleem, A.; Rasul, A.; Faran Ashraf Baig, M.M.; Bin-Jumah, M.; Abdel Daim, M.M. Anticancer Natural Medicines: An Overview of Cell Signaling and Other Targets of Anticancer Phytochemicals. Eur. J. Pharmacol. 2020, 888, 173488. [Google Scholar] [CrossRef]
- Chirumbolo, S.; Bjørklund, G.; Lysiuk, R.; Vella, A.; Lenchyk, L.; Upyr, T. Targeting Cancer with Phytochemicals via Their Fine Tuning of the Cell Survival Signaling Pathways. Int. J. Mol. Sci. 2018, 19, 3568. [Google Scholar] [CrossRef] [Green Version]
- Rutz, J.; Janicova, A.; Woidacki, K.; Chun, F.K.-H.; Blaheta, R.A.; Relja, B. Curcumin—A Viable Agent for Better Bladder Cancer Treatment. Int. J. Mol. Sci. 2020, 21, 3761. [Google Scholar] [CrossRef]
- Miyata, Y.; Shida, Y.; Hakariya, T.; Sakai, H. Anti-Cancer Effects of Green Tea Polyphenols Against Prostate Cancer. Molecules 2019, 24, 193. [Google Scholar] [CrossRef] [Green Version]
- Zaffaroni, N.; Beretta, G.L. Resveratrol and Prostate Cancer: The Power of Phytochemicals. Curr. Med. Chem. 2021, 28, 4845–4862. [Google Scholar] [CrossRef]
- Mirahmadi, M.; Azimi-Hashemi, S.; Saburi, E.; Kamali, H.; Pishbin, M.; Hadizadeh, F. Potential Inhibitory Effect of Lycopene on Prostate Cancer. Biomed. Pharmacother. 2020, 129, 110459. [Google Scholar] [CrossRef]
- Leone, A.; Diorio, G.; Sexton, W.; Schell, M.; Alexandrow, M.; Fahey, J.W.; Kumar, N.B. Sulforaphane for the Chemoprevention of Bladder Cancer: Molecular Mechanism Targeted Approach. Oncotarget 2017, 8, 35412–35424. [Google Scholar] [CrossRef] [Green Version]
- Salehi, B.; Fokou, P.V.T.; Yamthe, L.R.T.; Tali, B.T.; Adetunji, C.O.; Rahavian, A.; Mudau, F.N.; Martorell, M.; Setzer, W.N.; Rodrigues, C.F.; et al. Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents. Nutrients 2019, 11, 1483. [Google Scholar] [CrossRef] [Green Version]
- Xia, Y.; Chen, R.; Lu, G.; Li, C.; Lian, S.; Kang, T.-W.; Jung, Y.D. Natural Phytochemicals in Bladder Cancer Prevention and Therapy. Front. Oncol. 2021, 11, 652033. [Google Scholar] [CrossRef]
- Vasan, N.; Baselga, J.; Hyman, D.M. A View on Drug Resistance in Cancer. Nature 2019, 575, 299–309. [Google Scholar] [CrossRef] [Green Version]
- Nikolaou, M.; Pavlopoulou, A.; Georgakilas, A.G.; Kyrodimos, E. The Challenge of Drug Resistance in Cancer Treatment: A Current Overview. Clin. Exp. Metastasis 2018, 35, 309–318. [Google Scholar] [CrossRef]
- Somers-Edgar, T.J.; Scandlyn, M.J.; Stuart, E.C.; Le Nedelec, M.J.; Valentine, S.P.; Rosengren, R.J. The Combination of Epigallocatechin Gallate and Curcumin Suppresses ER Alpha-Breast Cancer Cell Growth in Vitro and in Vivo. Int. J. Cancer 2008, 122, 1966–1971. [Google Scholar] [CrossRef] [PubMed]
- Dai, W.; Ruan, C.; Zhang, Y.; Wang, J.; Han, J.; Shao, Z.; Sun, Y.; Liang, J. Bioavailability Enhancement of EGCG by Structural Modification and Nano-Delivery: A Review. J. Funct. Foods 2020, 65, 103732. [Google Scholar] [CrossRef]
- Cai, Z.-Y.; Li, X.-M.; Liang, J.-P.; Xiang, L.-P.; Wang, K.-R.; Shi, Y.-L.; Yang, R.; Shi, M.; Ye, J.-H.; Lu, J.-L.; et al. Bioavailability of Tea Catechins and Its Improvement. Molecules 2018, 23, 2346. [Google Scholar] [CrossRef] [Green Version]
- Lambert, J.D.; Sang, S.; Hong, J.; Kwon, S.-J.; Lee, M.-J.; Ho, C.-T.; Yang, C.S. Peracetylation as a Means of Enhancing in Vitro Bioactivity and Bioavailability of Epigallocatechin-3-Gallate. Drug Metab. Dispos. 2006, 34, 2111–2116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Chiou, Y.-S.; Ma, N.J.-L.; Sang, S.; Ho, C.-T.; Wang, Y.-J.; Pan, M.-H. Peracetylated (−)-Epigallocatechin-3-Gallate (AcEGCG) Potently Suppresses Dextran Sulfate Sodium-Induced Colitis and Colon Tumorigenesis in Mice. J. Agric. Food Chem. 2012, 60, 3441–3451. [Google Scholar] [CrossRef]
- Chao, J.; Lau, W.K.-W.; Huie, M.J.; Ho, Y.-S.; Yu, M.-S.; Lai, C.S.-W.; Wang, M.; Yuen, W.-H.; Lam, W.H.; Chan, T.H.; et al. A Pro-Drug of the Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate (EGCG) Prevents Differentiated SH-SY5Y Cells from Toxicity Induced by 6-Hydroxydopamine. Neurosci. Lett. 2010, 469, 360–364. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, S.-C.; Chan, W.-K.; Lee, T.-W.; Lam, W.-H.; Wang, X.; Chan, T.-H.; Wong, Y.-C. Effect of a Prodrug of the Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate on the Growth of Androgen-Independent Prostate Cancer in Vivo. Nutr. Cancer 2008, 60, 483–491. [Google Scholar] [CrossRef]
- Wang, J.; Man, G.C.W.; Chan, T.H.; Kwong, J.; Wang, C.C. A Prodrug of Green Tea Polyphenol (-)-Epigallocatechin-3-Gallate (Pro-EGCG) Serves as a Novel Angiogenesis Inhibitor in Endometrial Cancer. Cancer Lett. 2018, 412, 10–20. [Google Scholar] [CrossRef]
- Yang, Q.-Q.; Wei, X.-L.; Fang, Y.-P.; Gan, R.-Y.; Wang, M.; Ge, Y.-Y.; Zhang, D.; Cheng, L.-Z.; Corke, H. Nanochemoprevention with Therapeutic Benefits: An Updated Review Focused on Epigallocatechin Gallate Delivery. Crit. Rev. Food Sci. Nutr. 2020, 60, 1243–1264. [Google Scholar] [CrossRef]
- Hamano, N.; Böttger, R.; Lee, S.E.; Yang, Y.; Kulkarni, J.A.; Ip, S.; Cullis, P.R.; Li, S.-D. Robust Microfluidic Technology and New Lipid Composition for Fabrication of Curcumin-Loaded Liposomes: Effect on the Anticancer Activity and Safety of Cisplatin. Mol. Pharm. 2019, 16, 3957–3967. [Google Scholar] [CrossRef]
- Nocito, M.C.; De Luca, A.; Prestia, F.; Avena, P.; La Padula, D.; Zavaglia, L.; Sirianni, R.; Casaburi, I.; Puoci, F.; Chimento, A.; et al. Antitumoral Activities of Curcumin and Recent Advances to ImProve Its Oral Bioavailability. Biomedicines 2021, 9, 1476. [Google Scholar] [CrossRef]
- Zheng, B.; McClements, D.J. Formulation of More Efficacious Curcumin Delivery Systems Using Colloid Science: Enhanced Solubility, Stability, and Bioavailability. Molecules 2020, 25, 2791. [Google Scholar] [CrossRef] [PubMed]
- Konstantinov, S.M.; Kostovski, A.; Berger, M.R. Will Human Urinary Bladder Carcinoma Respond to Treatment with Alkylphosphocholines and Curcumin? Facta Univ. 2002, 9, 70–73. [Google Scholar]
- Hauser, P.J.; Han, Z.; Sindhwani, P.; Hurst, R. Sensitivity of Bladder Cancer Cells to Curcumin and Its Derivatives Depends on the Extracellular Matrix. Anticancer Res. 2007, 27, 737–740. [Google Scholar] [PubMed]
- Choi, H.Y.; Lim, J.E.; Hong, J.H. Curcumin interrupts the interaction between the androgen receptor and Wnt/β-catenin signaling pathway in LNCaP prostate cancer cells. Prostate Cancer Prostatic Dis. 2010, 13, 343–349. [Google Scholar] [CrossRef] [Green Version]
- Eslami, S.S.; Jafari, D.; Montazeri, H.; Sadeghizadeh, M.; Tarighi, P. Combination of Curcumin and Metformin Inhibits Cell Growth and Induces Apoptosis without Affecting the Cell Cycle in LNCaP Prostate Cancer Cell Line. Nutr. Cancer 2020, 73, 1026–1039. [Google Scholar] [CrossRef] [PubMed]
- Dhima, I.; Zerikiotis, S.; Lekkas, P.; Simos, Y.V.; Gkiouli, M.; Vezyraki, P.; Dounousi, E.; Ragos, V.; Giannakopoulos, X.; Baltogiannis, D.; et al. Curcumin Acts as a Chemosensitizer for Leiomyosarcoma Cells In Vitro But Fails to Mediate Antioxidant Enzyme Activity in Cisplatin-Induced Experimental Nephrotoxicity in Rats. Integr. Cancer Ther. 2019, 18. [Google Scholar] [CrossRef] [Green Version]
- Muthoosamy, K.; Abubakar, I.B.; Bai, R.G.; Loh, H.-S.; Manickam, S. Exceedingly Higher co-loading of Curcumin and Paclitaxel onto Polymer-functionalized Reduced Graphene Oxide for Highly Potent Synergistic Anticancer Treatment. Sci. Rep. 2016, 6, 32808. [Google Scholar] [CrossRef] [Green Version]
- Cianfruglia, L.; Minnelli, C.; Laudadio, E.; Scirè, A.; Armeni, T. Side Effects of Curcumin: Epigenetic and Antiproliferative Implications for Normal Dermal Fibroblast and Breast Cancer Cells. Antioxidants 2019, 8, 382. [Google Scholar] [CrossRef] [Green Version]
- Shenouda, N.S.; Zhou, C.; Browning, J.D.; Ansell, P.J.; Sakla, M.S.; Lubahn, D.B.; Macdonald, R.S. Phytoestrogens in Common Herbs Regulate Prostate Cancer Cell Growth in Vitro. Nutr. Cancer 2004, 49, 200–208. [Google Scholar] [CrossRef]
- Luo, K.-W.; Lung, W.-Y.; Xie, C.; Luo, X.-L.; Huang, W.-R. EGCG inhibited bladder cancer T24 and 5637 cell proliferation and migration via PI3K/AKT pathway. Oncotarget 2018, 9, 12261–12272. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sinjari, B.; Pizzicannella, J.; D’Aurora, M.; Zappacosta, R.; Gatta, V.; Fontana, A.; Trubiani, O.; Diomede, F. Curcumin/Liposome Nanotechnology as Delivery Platform for Anti-inflammatory Activities via NFkB/ERK/pERK Pathway in Human Dental Pulp Treated With 2-HydroxyEthyl MethAcrylate (HEMA). Front. Physiol. 2019, 10, 633. [Google Scholar] [CrossRef]
- Mohammadi, S.S.; Vaezi, Z.; Shojaedin-Givi, B.; Naderi-Manesh, H. Chemiluminescent liposomes as a theranostic carrier for detection of tumor cells under oxidative stress. Anal. Chim. Acta 2019, 1059, 113–123. [Google Scholar] [CrossRef]
- Verheijen, M.; Lienhard, M.; Schrooders, Y.; Clayton, O.; Nudischer, R.; Boerno, S.; Timmermann, B.; Selevsek, N.; Schlapbach, R.; Gmuender, H.; et al. DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro. Sci. Rep. 2019, 9, 4641. [Google Scholar] [CrossRef] [Green Version]
- Galvao, J.; Davis, B.; Tilley, M.; Normando, E.; Duchen, M.R.; Cordeiro, M.F. Unexpected low-dose toxicity of the universal solvent DMSO. FASEB J. 2013, 28, 1317–1330. [Google Scholar] [CrossRef]
- Rizeq, B.; Gupta, I.; Ilesanmi, J.; Alsafran, M.; Rahman, M.; Ouhtit, A. The Power of Phytochemicals Combination in Cancer Chemoprevention. J. Cancer 2020, 11, 4521–4533. [Google Scholar] [CrossRef] [PubMed]
- Ghosh, A.K.; Kay, N.E.; Secreto, C.R.; Shanafelt, T.D. Curcumin Inhibits Prosurvival Pathways in Chronic Lymphocytic Leukemia B Cells and May Overcome Their Stromal Protection in Combination with EGCG. Clin. Cancer Res. 2009, 15, 1250–1258. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- La Barbera, G.; Capriotti, A.L.; Caracciolo, G.; Cavaliere, C.; Cerrato, A.; Montone, C.M.; Piovesana, S.; Pozzi, D.; Quagliarini, E.; Laganà, A. A comprehensive analysis of liposomal biomolecular corona upon human plasma incubation: The evolution towards the lipid corona. Talanta 2019, 209, 120487. [Google Scholar] [CrossRef] [PubMed]
- Foteini, P.; Pippa, N.; Naziris, N.; Demetzos, C. Physicochemical study of the protein–liposome interactions: Influence of liposome composition and concentration on protein binding. J. Liposome Res. 2019, 29, 313–321. [Google Scholar] [CrossRef]
- Pozzi, D.; Caracciolo, G.; Digiacomo, L.; Colapicchioni, V.; Palchetti, S.; Capriotti, A.L.; Cavaliere, C.; Chiozzi, R.Z.; Puglisi, A.; Laganà, A. The biomolecular corona of nanoparticles in circulating biological media. Nanoscale 2015, 7, 13958–13966. [Google Scholar] [CrossRef]
- Roberts, S.A.; Lee, C.; Singh, S.; Agrawal, N. Versatile Encapsulation and Synthesis of Potent Therapeutic Liposomes by Thermal Equilibration. bioRxiv 2021. [Google Scholar] [CrossRef]
Compound | Particle Size (±SD) [nm] | PDI a | Concentration (±SD) [Particles/mL] |
---|---|---|---|
CUR | 129.9 ± 45.0 | 0.120 | 1.48 × 1013 ± 1.87 × 1012 |
pEGCG | 136.8 ± 33.5 | 0.060 | 1.39 × 1013 ± 8.47 × 1011 |
CUR+pEGCG | 123.3 ± 41.8 | 0.115 | 8.89 × 1012 ± 1.29 × 1012 |
Temperature | Curcumin | |||
Storage Time [Days] | Particle Size (±SD) [nm] | PDI a | Concentration (±SD) [Particles/mL] | |
4–8 °C | 0 | 133.8 ± 51.5 | 0.148 | 1.54 × 1013 ± 2.31 × 1012 |
1 | 130.9 ± 23.6 | 0.033 | 2.51 × 1013 ± 4.11 × 1012 | |
7 | 133.6 ± 32.2 | 0.058 | 2.86 × 1013 ± 2.07 × 1012 | |
14 | 133.0 ± 48.0 | 0.130 | 4.39 × 1013 ± 1.04 × 1012 | |
21 | 132.1 ± 38.4 | 0.085 | 5.05 × 1013 ± 5.45 × 1012 | |
28 | 133.1 ± 41.1 | 0.095 | 3.51 × 1013 ± 5.87 × 1012 | |
20 °C | 1 | 139.4 ± 35.5 | 0.065 | 2.17 × 1013 ± 1.63 × 1012 |
7 | 130.1 ± 26.5 | 0.041 | 1.72 × 1013 ± 2.44 × 1011 | |
14 | 128.0 ± 41.6 | 0.106 | 2.04 × 1013 ± 8.49 × 1011 | |
21 | 125.8 ± 31.3 | 0.062 | 1.45 × 1013 ± 4.75 × 1011 | |
28 | 129.7 ± 42.5 | 0.107 | 2.49 × 1013 ± 3.66 × 1012 | |
Temperature | pEGCG | |||
Storage Time [Days] | Particle Size (±SD) [nm] | PDI a | Concentration (±SD) [Particles/mL] | |
4–8 °C | 0 | 129.8 ± 30.3 | 0.054 | 1.28 × 1013 ± 8.67 × 1011 |
1 | 134.0 ± 31.6 | 0.056 | 2.22 × 1013 ± 5.67 × 1012 | |
7 | 132.2 ± 32.0 | 0.059 | 1.45 × 1013 ± 2.73 × 1012 | |
14 | 122.7 ± 36.9 | 0.090 | 3.66 × 1013 ± 2.39 × 1012 | |
21 | 131.7 ± 41.9 | 0.101 | 3.49 × 1013 ± 3.37 × 1012 | |
28 | 127.2 ± 38.6 | 0.092 | 4.05 × 1013 ± 9.78 × 1011 | |
20 °C | 1 | 135.1 ± 41.2 | 0.093 | 5.37 × 1013 ± 5.03 × 1011 |
7 | 129.5 ± 33.7 | 0.068 | 1.21 × 1013 ± 1.60 × 1012 | |
14 | 128.2 ± 44.2 | 0.119 | 2.99 × 1013 ± 1.62 × 1012 | |
21 | 144.4 ± 70.1 | 0.236 | 1.80 × 1013 ± 4.22 × 1011 | |
28 | 145.6 ± 48.0 | 0.109 | 1.60 × 1013 ± 1.04 × 1012 |
Time [Days] | CUR C/C0 | SD | pEGCG C/C0 | SD | CUR C/C0 (CUR+pEGCG) | SD | pEGCG C/C0 (CUR+pEGCG) | SD |
---|---|---|---|---|---|---|---|---|
0 | 100.00% | 0.18% | 100.00% | 0.84% | 100.00% | 0.61% | 100.00% | 1.58% |
7 | 97.93% | 0.61% | 24.98% | 2.81% | 51.96% | 0.62% | 20.76% | 0.38% |
14 | 63.92% | 1.35% | 19.82% | 0.26% | 50.95% | 0.50% | 14.64% | 0.46% |
21 | 61.64% | 0.05% | 15.03% | 2.89% | 50.65% | 1.37% | 14.30% | 0.00% |
28 | 58.21% | 0.90% | 9.67% | 9.01% | 46.67% | 0.72% | 10.65% | 0.47% |
Time [Days] | CUR C/C0 | SD | pEGCG C/C0 | SD | CUR C/C0 (CUR+pEGCG) | SD | pEGCG C/C0 (CUR+pEGCG) | SD |
---|---|---|---|---|---|---|---|---|
0 | 100.00% | 0.18% | 100.00% | 0.84% | 100.00% | 0.61% | 100.00% | 1.58% |
7 | 89.16% | 1.48% | 19.58% | 3.09% | 57.15% | 0.18% | 21.81% | 2.52% |
14 | 43.00% | 0.09% | 19.07% | 2.93% | 53.67% | 0.03% | 16.82% | 0.10% |
21 | 42.84% | 1.09% | 17.98% | 0.86% | 51.81% | 0.31% | 13.27% | 1.13% |
28 | 40.94% | 1.06% | 10.77% | 2.72% | 51.27% | 3.38% | 9.87% | 0.34% |
IC50 [µM] | ||||
---|---|---|---|---|
Cell Line | Curcumin | pEGCG | ||
24 h | 48 h | 24 h | 48 h | |
5637 | 17.95 ± 6.68 | 11.25 ± 2.47 | 84.08 ± 1.09 | 76.73 ± 0.24 |
LNCaP | 30.61 ± 6.95 | 19.66 ± 3.78 | 62.45 ± 12.10 | 60.98 ± 9.25 |
MRC-5 | 38.73 ± 3.39 | 25.81 ± 1.61 | 73.82 ± 6.23 | 65.55 ± 5.92 |
Cell Line | Curcumin | pEGCG | Curcumin+pEGCG | |||
---|---|---|---|---|---|---|
24 h | 48 h | 24 h | 48 h | 24 h | 48 h | |
5637 | 17.12 ± 4.09 | 12.27 ± 2.91 | >40 | >40 | 19.50 ± 3.23 | 15.33 ± 2.03 |
LNCaP | 38.96 ± 2.90 | 22.06 ± 3.14 | >40 | >40 | >40 | >40 |
MRC-5 | >40 | >40 | >40 | >40 | >40 | >40 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Piwowarczyk, L.; Kucinska, M.; Tomczak, S.; Mlynarczyk, D.T.; Piskorz, J.; Goslinski, T.; Murias, M.; Jelinska, A. Liposomal Nanoformulation as a Carrier for Curcumin and pEGCG—Study on Stability and Anticancer Potential. Nanomaterials 2022, 12, 1274. https://doi.org/10.3390/nano12081274
Piwowarczyk L, Kucinska M, Tomczak S, Mlynarczyk DT, Piskorz J, Goslinski T, Murias M, Jelinska A. Liposomal Nanoformulation as a Carrier for Curcumin and pEGCG—Study on Stability and Anticancer Potential. Nanomaterials. 2022; 12(8):1274. https://doi.org/10.3390/nano12081274
Chicago/Turabian StylePiwowarczyk, Ludwika, Malgorzata Kucinska, Szymon Tomczak, Dariusz T. Mlynarczyk, Jaroslaw Piskorz, Tomasz Goslinski, Marek Murias, and Anna Jelinska. 2022. "Liposomal Nanoformulation as a Carrier for Curcumin and pEGCG—Study on Stability and Anticancer Potential" Nanomaterials 12, no. 8: 1274. https://doi.org/10.3390/nano12081274